Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Eunice S. Wang, MD, Jessica K. Altman, MD, Kristen Pettit, Stephane De Botton, Roland P Walter, MDPhD, Pierre Fenaux, MD PhD, Francis Burrows, PhD, Blake E. Tomkinson, PhDMBA, Bridget Martell, MA, MD, Amir T. Fathi, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-134942

Published: 2020

Journal Articles

Identification of Tipifarnib Sensitivity Biomarkers in T-Cell Tumor Cell Lines

Ruth Alonso Alonso, PhD, Rufino Mondejar García, PhD, Jose Pedro Vaqué Díez, PhD, Nuria García Díaz, PhDcandidate, Cristina Pérez Menéndez, PhD, Francis Burrows, PhD, Catherine Scholz, PharmD, Antonio Gualberto, PhD MD, Miguel A. Piris, PhD MD

Blood (2018) 132 (Supplement 1): 2851.

https://doi.org/10.1182/blood-2018-99-118291

Published: 2018

Journal Articles

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib: Preliminary Results from an Open-Label, Phase II Study in Relapsed or Refractory Peripheral T-Cell Lymphoma

Thomas E Witzig, MD, Lubomir Sokol, MD PhD, Eric Jacobsen, MD, Ranjana H. Advani, MD, Francine M Foss, MD, Rufino Mondejar, PhD, Miguel Angel Piris, PhDMD, James Bolognese, PhD, Francis Burrows, PhD, Linda Kessler, BA, Karen Bracken, MHS, Vishnu Mishra, PhD, Catherine Scholz, PharmD, Antonio Gualberto, PhD MD

Blood (2017) 130 (Supplement 1): 2788.

https://doi.org/10.1182/blood.V130.Suppl_1.2788.2788

Published: 2017

Journal Articles

In Vivo Treatment with TG-02 Results in Increased Mobilization and Sensitization of Leukemia Stem Cells to Chemotherapeutic Agents

Zeena Salman, MD MPH, Jeanne P. De Leon, Eric J. Feldman, MD, Francis Burrows, PhD, Gail J. Roboz, MD, Monica L. Guzman, PhD

Blood (2014) 124 (21): 3765.

https://doi.org/10.1182/blood.V124.21.3765.3765

Published: 2014

Journal Articles

Leukemia Stem/Progenitor Cells From AML Patients Treated With The Multi-Kinase Inhibitor TG02 Demonstrate Increased Proliferation and Are Sensitized To Chemotherapeutic Agents

Monica L. Guzman, PhD, Wen Xie, MS, Jeanne P. De Leon, Francis Burrows, PhD, Eric J. Feldman, MD, Gail J. Roboz, MD

Blood (2013) 122 (21): 3892.

https://doi.org/10.1182/blood.V122.21.3892.3892

Published: 2013

Journal Articles

Dual Inhibition Of Mcl-1 By The Combination Of Carfilzomib and TG02 In Multiple Myeloma

Katelyn G. Barnhart, Shannon M. Matulis, Ph.D., Sadae Hitosugi, MS, Cathy Sharp, R.N., Francis Burrows, PhD, Ajay K. Nooka, MD, MPH, Jonathan L. Kaufman, MD, Sagar Lonial, M.D., Lawrence H. Boise, PhD

Blood (2013) 122 (21): 3171.

https://doi.org/10.1182/blood.V122.21.3171.3171

Published: 2013

Journal Articles

Effectiveness of Transcriptional CDK Inhibitors in Targeting Non-Proliferating CD34+CD38- AML Cells,

Monica Pallis, PhD, Francis Burrows, PhD, Abigail Whittall, B Med Sci, Claire Seedhouse, PhD, Nicholas Boddy, B Med Sci, Nigel H. Russell, MD

Blood (2011) 118 (21): 3482.

https://doi.org/10.1182/blood.V118.21.3482.3482

Published: 2011

Journal Articles

The Multi-Kinase Inhibitor TG02 targets CD34+CD38-CD123+ AML Cells

Monica Pallis, PhD, Francis Burrows, PhD, Nigel H. Russell, MD

Blood (2010) 116 (21): 1823.

https://doi.org/10.1182/blood.V116.21.1823.1823

Published: 2010

Journal Articles

Antimyeloma Action of the Multikinase Inhibitor TG02

Stela Álvarez-Fernández, Susana Hernández-García, Xi Chen, Enrique M. Ocio, Jr., MD, PhD, Bruno Paiva, Kay R. Meshow, Lynn A. Cheatham, Francis Burrows, PhD, Jesús F. San Miguel, Sr., MD, PhD, Atanasio Pandiella, Sr., MD, PhD

Blood (2010) 116 (21): 4062.

https://doi.org/10.1182/blood.V116.21.4062.4062

Published: 2010

Journal Articles

The Synthetic Hest Shock Protein (Hsp) 90 Inhibitor EC141 Induces Degradation of the Bcr-Abl p190 Protein and Apoptosis of Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Cells.

Alessandra Ferrajoli, MD, Yongtao Wang, MD, Susan M. O’Brien, MD, Stefan H. Faderl, MD, David M. Harris, BS, Quin Van, BS, Inbal Hallevi, PhD, Zhiming Liu, BS, Patricia E. Koch, MS, John Sensintaffar, MS, Francis Burrows, PhD, Hagop M. Kantarjian, MD, Michael J. Keating, MB, BS, Zeev Estrov, MD

Blood (2007) 110 (11): 2784.

https://doi.org/10.1182/blood.V110.11.2784.2784

Published: 2007

NARROW

Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Identification of Tipifarnib Sensitivity Biomarkers in T-Cell Tumor Cell Lines

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib: Preliminary Results from an Open-Label, Phase II Study in Relapsed or Refractory Peripheral T-Cell Lymphoma

In Vivo Treatment with TG-02 Results in Increased Mobilization and Sensitization of Leukemia Stem Cells to Chemotherapeutic Agents

Leukemia Stem/Progenitor Cells From AML Patients Treated With The Multi-Kinase Inhibitor TG02 Demonstrate Increased Proliferation and Are Sensitized To Chemotherapeutic Agents

Dual Inhibition Of Mcl-1 By The Combination Of Carfilzomib and TG02 In Multiple Myeloma

Effectiveness of Transcriptional CDK Inhibitors in Targeting Non-Proliferating CD34+CD38- AML Cells,

The Multi-Kinase Inhibitor TG02 targets CD34+CD38-CD123+ AML Cells

Antimyeloma Action of the Multikinase Inhibitor TG02

The Synthetic Hest Shock Protein (Hsp) 90 Inhibitor EC141 Induces Degradation of the Bcr-Abl p190 Protein and Apoptosis of Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only